Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials-Reference-Cited by-同舟云学术

Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials

Published:2015-12-23 Issue:3 Volume:18 Page:295-299
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Abbas A. S.¹^ORCID,Dehbi H.-M.²,Ray K. K.¹

Affiliation:

1. Department of Primary Care and Public Health; School of Public Health, Imperial College London; London UK

2. Department of Epidemiology and Biostatistics; School of Public Health, Imperial College London; London UK

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12595/fullpdf

Reference13 articles.

1. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes;Bianchi;Diabetes Care,2009

2. Heart disease and stroke statistics-2015 update: a report from the american heart association;Mozaffarian;Circulation,2015

3. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials;Ray;Lancet,2009

4. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes;Nathan;N Engl J Med,2005

5. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes 2008 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review;Frontiers in Pharmacology;2024-01-16

2. Expert eValuation of Efficacy and Rationality of Vildagliptin “EVER-Vilda”: An Indian Perspective;Clinical Medicine Insights: Endocrinology and Diabetes;2024-01

3. Dipeptidyl peptidase-4 inhibitors reduce the incidence of first cardiovascular events in Japanese diabetic patients;Heart and Vessels;2023-07-31

4. Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual;Diabetes and Cardiovascular Disease;2023

5. Metformin, Sulfonylureas, DPP-4 Inhibitors and Cardiovascular Outcomes in Type 2 DM;Diabetes and Cardiovascular Disease;2023